biostudies-literatureUnknown73(9)Singh P<h4>Purpose</h4>To evaluate the efficacy and safety of 1.25% pilocarpine compared to placebo for the treatment of presbyopia.<h4>Methods</h4>This multicenter, randomized, double-masked clinical trial compared pilocarpine 1.25% to placebo in presbyopic individuals aged 45-55 years, meeting standard near vision impairment criteria. Participants were randomized 1:1 using a computer-generated sequence, with identical, unmarked bottles ensuring masking. Distance-corrected near visual acuity (DCNVA) and distance-corrected intermediate visual acuity (DCIVA) were assessed under mesopic and photopic conditions across multiple visits (days 1, 3, 7, 14, and 30). The primary outcome was a ≥ 3-line gain in mesopic, high-contrast, binocular DCNVA at day 30, hour 3. Secondary outcomes included photopic aIndian journal of ophthalmology1251-1257https://www.ebi.ac.uk/biostudies/studies/S-EPMC12448526biostudies-literatureEfficacy and safety of pilocarpine hydrochloride ophthalmic solution USP 1.25% w/v versus placebo ophthalmic solution for the treatment of presbyopia - A multicentric clinical trial.PMC12448526Datta ANivean MGarasiya TSingh PAjila VSengupta SfalseEfficacy and safety of pilocarpine hydrochloride ophthalmic solution USP 1.25% w/v versus placebo ophthalmic solution for the treatment of presbyopia - A multicentric clinical trial.<h4>Purpose</h4>To evaluate the efficacy and safety of 1.25% pilocarpine compared to placebo for the treatment of presbyopia.<h4>Methods</h4>This multicenter, randomized, double-masked clinical trial compared pilocarpine 1.25% to placebo in presbyopic individuals aged 45-55 years, meeting standard near vision impairment criteria. Participants were randomized 1:1 using a computer-generated sequence, with identical, unmarked bottles ensuring masking. Distance-corrected near visual acuity (DCNVA) and distance-corrected intermediate visual acuity (DCIVA) were assessed under mesopic and photopic conditions across multiple visits (days 1, 3, 7, 14, and 30). The primary outcome was a ≥ 3-line gain in mesopic, high-contrast, binocular DCNVA at day 30, hour 3. Secondary outcomes included photopic a2025-01-01T00:00:00Z2025 Sep2026-07-12T03:16:09.449Z2026-07-12T03:09:16.421ZS-EPMC124485264088014310.4103/IJO.IJO_680_25